GlassScriptPhysician profile
Isaac Matthew Chambers
NPI 1497168777
$5,824.71
in general payments reported to CMS, 2019-2025
59 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.22 · 2022: $544 · 2023: $1,466 · 2024: $2,057 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,068 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,068.07 |
| Education | $198.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $485.88 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $458.10 | 2022-2025 | |
| Celgene Corporation | $364.10 | 2022-2025 | Pomalyst, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $310.79 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $281.25 | 2022-2025 | Erleada, Darzalex, Rybrevant |
| Astellas Pharma US INC | $222.90 | 2024-2025 | Xtandi, Vyloy |
| Glaxosmithkline, LLC. | $221.43 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $200.49 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Array Biopharma INC | $183.96 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $183.59 | 2023-2025 | Zoladex, Xermelo |
| E.R. Squibb & Sons, L.L.C. | $176.28 | 2022-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $163.28 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $156.88 | 2023-2025 | Verzenio, Retevmo, Jaypirca |
| Abbvie INC. | $155.03 | 2024-2025 | |
| Genentech USA, INC. | $151.90 | 2022-2025 | Tecentriq, Polivy |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $126.30 | 2023-2025 | Cabometyx |
| Seagen INC. | $123.76 | 2022-2023 | Tukysa, Adcetris |
| Sobi, INC | $116.61 | 2024-2025 | |
| Amgen INC. | $113.38 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Merck Sharp & Dohme LLC | $105.43 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Puma Biotechnology, INC. | $92.15 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $83.91 | 2023-2025 | Orgovyx |
| Kite Pharma, INC. | $80.98 | 2022-2025 | Yescarta |
| Novocure INC. | $79.53 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Incyte Corporation | $75.64 | 2024 | Monjuvi, Jakafi |
| Springworks Therapeutics, INC. | $75.49 | 2024-2025 | Ogsiveo |
| Stemline Therapeutics INC. | $70.64 | 2023-2025 | Orserdu |
| Eisai INC. | $68.24 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $64.09 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Aveo Pharmaceuticals, INC. | $63.99 | 2022-2024 | Fotivda |
| Taiho Oncology, INC. | $56.27 | 2022-2024 | |
| Mirati Therapeutics, INC. | $49.51 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $44.60 | 2024-2025 | Tivdak |
| Syndax Pharmaceuticals, INC. | $41.61 | 2025 | |
| Servier Pharmaceuticals LLC | $41.38 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $37.55 | 2024-2025 | Empaveli |
| Pharmacosmos Therapeutics INC. | $33.99 | 2024 | Cosela |
| Alexion Pharmaceuticals, INC. | $32.67 | 2023-2024 | Ultomiris |
| Genzyme Corporation | $32.00 | 2023 | |
| Pharmaessentia USA Corporation | $31.99 | 2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $31.71 | 2025 | Onivyde |
| Jazz Pharmaceuticals INC. | $25.57 | 2025 | |
| Medtronic, INC. | $23.03 | 2022 | |
| Tactile Systems Technology INC | $22.02 | 2025 | Nimbl, Flexitouch Plus |
| Sun Pharmaceutical Industries INC. | $21.97 | 2025 | |
| Daiichi Sankyo INC. | $21.44 | 2025 | Enhertu |
| Geron Corporation | $21.23 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $19.94 | 2022 | |
| Kyowa Kirin, INC. | $19.64 | 2024 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $19.49 | 2025 | Libtayo |
| Emd Serono, INC. | $18.41 | 2024 | |
| Immunocore Limited | $17.75 | 2024 | Kimmtrak |
| Legend Biotech USA INC. | $17.22 | 2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $17.13 | 2023 | Pyrukynd |
| Caris Mpi, INC. | $15.44 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $15.00 | 2022 | |
| Beigene USA, INC. | $14.31 | 2022 | |
| G1 Therapeutics, INC. | $14.03 | 2023 | Cosela |
| Myriad Genetic Laboratories, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.